Mesalazin Orion

Mesalazine, the active ingredient in Mesalazin Orion, is an Aminosalicylate presented as an oral formulation for oral use. It is employed to treat ulcerative colitis and Crohn's disease, providing anti‑inflammatory relief in the intestinal mucosa of adult patients.

GNH USA supplies Mesalazin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for cross‑border distribution, ensuring product integrity throughout the supply chain, and timely delivery to end‑users.

Mesalazine acts locally in the gastrointestinal tract to reduce inflammation associated with inflammatory bowel disease.

Ulcerative colitis: induces remission and maintains symptom control by decreasing mucosal inflammation. Crohn's disease: helps control intestinal inflammation, reducing abdominal pain and diarrhea. Maintenance therapy for ulcerative colitis: provides ongoing anti‑inflammatory effect to prevent disease flare‑ups.

Mesalazine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or upset stomach. - Abdominal cramping or pain. - Headache. - Increased flatulence or gas.

Serious or Rare Side Effects: - Myocarditis or pericarditis. - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, several safety considerations should be observed. - Renal function monitoring: assess serum creatinine before and during therapy. - Blood counts: perform periodic complete blood count to detect leukopenia or anemia. - Pregnancy and lactation: use only if benefits outweigh risks; consult healthcare provider. - Drug hypersensitivity: discontinue if rash, fever, or organ involvement occurs. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mesalazine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Azathioprine or 6‑mercaptopurine: may enhance myelosuppression. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Oral corticosteroids: may increase risk of infection. - Diuretics: may affect renal clearance of mesalazine.